2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
4
Completed
4
Active not recruiting
3
Terminated
2
Enrolling by invitation
1
Available
1
Approved for marketing
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Recurrence
2
Waldenstrom Macroglobulinemia
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
391
Carboplatin
344
Gemcitabine
332
pembrolizumab
331
Cisplatin
328
Paclitaxel
298
Radiotherapy
297
Docetaxel
287
Bevacizumab
253
Rituximab
234
Capecitabine
224
Nivolumab
222
Dexamethasone
206
Fluorouracil
190
fludarabine
178
Oxaliplatin
177
Pemetrexed
153
Doxorubicin
153
Irinotecan
148
Leucovorin
144
Etoposide
144
Cytarabine
134
Cetuximab
130
fludarabine phosphate
129
Bortezomib
129
Lenalidomide
126
Filgrastim
120
Erlotinib Hydrochloride
120
Temozolomide
113
Radiosurgery
113
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts
NCT03624036
2023-11-18
ZUMA-8
Gilead Sciences
Phase 1
Terminated
16 enrolled
17 charts